TNF and psoriasis: Our data suggest that targeting IL-36R signaling, for example in the context of generalized pustular psoriasis or other forms of psoriasis [43] may be considered as a new, safe therapeutic strategy unlikely to compromise host immunity to mycobacteria, thereby reducing the risk of tuberculosis reactivation that is associated with TNF antagonists.